Cell Therapeutics’ Tosedostat Gets Back On Track
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA lifts clinical hold on first-in-class aminopeptidase inhibitor tosedostat, in investigator-sponsored Phase II trials for blood-related cancers as part of the company’s economic development strategy.
You may also be interested in...
CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress
Despite a sizeable price cut, uncertainty surrounding CTI’s non-Hodgkin’s lymphoma therapy Pixuvri has landed it with a second NICE rejection.
Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review
Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.
Cell Therapeutics Boosts Late-Stage Pipeline With Chroma's Tosedostat
Cell Therapeutics to co-develop tosedostat, a potential non-cytotoxic oral therapy for acute myeloid leukemia, with U.K. biotech Chroma Therapeutics.